GOSS
Gossamer Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.36
−3.09%Year over year
Reported trailing growth
- Revenue
- +32.4%
- EBITDA
- -59.0%
- EBIT
- -14.1%
- EPS
- —
- Free cash flow
- -32.9%
- Operating cash flow
- -5.4%
Forward estimates
Based on analyst estimates
- Revenue
- -79.6%
- EBITDA
- +73.3%
- EPS
- +64.3%
Three-year CAGR
- Revenue
- -57.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026